Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
HOUSTON, Might 18, 2022 (Globe NEWSWIRE) — Salarius Prescribed drugs, Inc. (Nasdaq: SLRX), a scientific-phase biopharmaceutical corporation producing prospective new medicines for individuals with sarcomas, pediatric cancers, and other solid and hematological cancers, right now announced that David Arthur, CEO of Salarius Prescribed drugs, will be pretty much presenting at the H.C. Wainwright Worldwide Expense Conference being held on Might 23-26, 2022.
The presentation will supply an overview of new organization and corporate achievements at Salarius as perfectly as focus on approaching milestones with the Company’s lead assets, seclidemstat and SP-3164.
Aspects of the presentation are as follows:
Celebration: H.C. Wainwright World-wide Financial commitment Convention
Day & Time: On need, beginning 7.00 a.m. ET, Tuesday May 24, 2022
Webcast Backlink: Salarius Pharmaceuticals Organization Presentation
A replay of the presentation will be readily available for 90 times at the link earlier mentioned or by traveling to www.salariuspharma.com. Registered investors will be in a position to timetable a one particular-on-one assembly by using the meeting portal.
About Salarius Pharmaceuticals
Salarius Prescribed drugs, Inc. is a scientific-phase biopharmaceutical firm producing most cancers therapies for individuals in have to have of new cure selections. Salarius’ product or service portfolio consists of seclidemstat (SP-2577), the company’s guide clinical candidate, which is staying researched as a probable treatment method for pediatric cancers, sarcomas, and other cancers with minimal procedure solutions, and SP-3164, an oral small molecule protein degrader. Seclidemstat is at the moment in a Period 1/2 clinical demo for relapsed/refractory Ewing sarcoma and find additional sarcomas that share a equivalent biology to Ewing sarcoma, also referred to as Ewing-relevant or FET-rearranged sarcomas. Seclidemstat has acquired Fast Track Designation, Orphan Drug Designation, and Exceptional Pediatric Illness Designation for Ewing sarcoma from the U.S. Meals and Drug Administration. Salarius is also checking out seclidemstat’s likely in several cancers with high unmet professional medical require, with a next Phase 1/2 scientific analyze in hematologic cancers, initiated by MD Anderson Most cancers Middle. Salarius has gained money guidance from the Countrywide Pediatric Cancer Basis to advance the Ewing sarcoma scientific system and was also a recipient of a Product or service Progress Award from the Cancer Avoidance and Analysis Institute of Texas (CPRIT). For much more details, make sure you check out salariuspharma.com or adhere to Salarius on Twitter and LinkedIn.
Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng (Traders)
Invoice Borden (Media)